- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Alvotech Breaks Ground for Biosimilar Development Facility
An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.
Alvotech has moved forward with expansion of its Reykjavik, Iceland, facilities for biosimilar development. The company has begun a 41,000-square-foot expansion of its high-tech center, which was established in the city in 2013.
Company officials said the new building will house biosimilar development, drug refills, offices, and warehouse space. A portion of the facility will be made available to the University of Iceland Biotechnology Department for collaborative work that includes student internships with Alvotech.
"It is a great delight to end this difficult year, which was marked by the battle against [coronavirus disease 2019] and subsequent gravities, with such a positive step toward the future evolution of the company,” Robert Wessman, chairman of the board of Alvotech, said in a statement. He said the expansion would provide the foundation for the commercialization of the company’s first biosimilars.
Not including this project, Alvotech has a 140,000-square-foot manufacturing and product development facility in Reykjavik; a second production center under construction in Changchun, China; and research and development operations in Julich and Hanover, Germany; Virginia; and Zurich, Switzerland.
Alvotech is developing biosimilars for autoimmune diseases, ophthalmology, and oncology. The company does not yet have any approved biosimilars, but in November 2020 Alvotech filed with the FDA and European Medicines Agency for approval of an adalimumab biosimilar (AVT02), referencing AbbVie’s Humira for the treatment of rheumatologic and gastrointestinal disorders.
In a recent presentation, Alvotech’s chief scientific officer described the company’s marketing strategy to launch biosimilars in multiple countries simultaneously. Toward this end, the company has signed numerous deals with global partners. Most recently, Alvotech signed an extended partnership agreement with Fuji Pharma in Japan. This covers the commercialization of 4 biosimilar medicines in that country.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.
